search
Documents
Automated Method Development of Oligonucleotide in Tissues Using Clarity OTX 96-Well Plate and High Resolution Mass Spectrometry (TN-0097)
As synthetic oligonucleotide (oligo) therapeutics move through the drug-development path, there has been an increasing need for TK and PK/PD studies in drug discovery and development. Because of the specificity, sensitivity, and shorter method development time which they afford, LC/MS/MS methods are preferred over ligand binding assays or ELISA. However, isolation of the oligonucleotide is required prior to analysis via LC/MS/MS; the clean and efficient extraction of synthetic oligonucleotides often proves challenging during method development (MD) due to low sample concentration, analyte recovery, and the possible co-extraction of matrix interferences.
Automated Method Development of Oligonucleotide in Tissues Using Clarity OTX 96-Well Plate and High Resolution Mass Spectrometry (TN-0097)
As synthetic oligonucleotide (oligo) therapeutics move through the drug-development path, there has been an increasing need for TK and PK/PD studies in drug discovery and development. Because of the specificity, sensitivity, and shorter method development time which they afford, LC/MS/MS methods are preferred over ligand binding assays or ELISA. However, isolation of the oligonucleotide is required prior to analysis via LC/MS/MS; the clean and efficient extraction of synthetic oligonucleotides often proves challenging during method development (MD) due to low sample concentration, analyte recovery, and the possible co-extraction of matrix interferences.
Document Type:
Technical Notes
Target Industries:
Brands:
Separation Modes:
Reversed Phase, Solid Phase Extraction
Phases:
Can't view? Disable your browser's pop-up blocker.
Automated Method Development of Oligonucleotide in Tissues Using Clarity OTX 96-Well Plate and High Resolution Mass Spectrometry (TN-0097)
As synthetic oligonucleotide (oligo) therapeutics move through the drug-development path, there has been an increasing need for TK and PK/PD studies in drug discovery and development. Because of the specificity, sensitivity, and shorter method development time which they afford, LC/MS/MS methods are preferred over ligand binding assays or ELISA. However, isolation of the oligonucleotide is required prior to analysis via LC/MS/MS; the clean and efficient extraction of synthetic oligonucleotides often proves challenging during method development (MD) due to low sample concentration, analyte recovery, and the possible co-extraction of matrix interferences.
| Target Industries: | Biopharmaceutical Analysis, Pharmaceutical |
| Techniques: | HPLC, HPLC Reversed Phase, Oligonucleotide Analysis, Oligonucleotide Synthesis, Sample Preparation, Solid Phase Extraction |
| Brands: | Clarity HPLC Columns, ClaritySPE |
| Separation Modes: | Reversed Phase, Solid Phase Extraction |
| Phases: | Clarity OTX |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide